Diabetes & Metabolic

Radiofrequency vapor ablation delivered through an endoscope working channel. The system is cleared for GI tract ablation, and the company is testing a duodenal mucosal ablation procedure for type 2 diabetes under an FDA IDE.

Makes the iLet automated insulin delivery system and the Mint patch pump, both of which dose insulin from continuous glucose monitor data.

Makes Biolinq Shine, a needle-free forearm patch whose microsensor array reads glucose from the top layers of skin. A color-coded LED on the patch shows the glucose range without a phone, and the device also logs activity and sleep.

Develops ReCET, an endoscopic catheter that applies non-thermal pulsed electric fields to the duodenum to treat type 2 diabetes. Breakthrough-designated and in a randomized, sham-controlled IDE study.

Builds Pivot, a tubeless insulin patch pump that delivers basal and bolus insulin over a three-day wear period. Aimed at people with diabetes who have not adopted existing pumps.

Developing a wearable microsensor that continuously measures molecules just beneath the skin, starting with glucose. Its filament is roughly a tenth the length of a conventional CGM's.

Sequel sells twiist, an automated insulin delivery pump that pairs with Abbott and Senseonics continuous glucose monitors and runs a dosing algorithm derived from Tidepool Loop.

UpDoc makes prescription software that collects diabetes data from patients through a voice and chat agent. It issues insulin dosing instructions within parameters set by the prescriber.